In-Depth Drug Research & Development

At Singh Biotechnology, LLC. we are discovering and developing proprietary therapeutic agents to target diseases. We perform specialized research and development using our novel technology platform to generate proprietary novel inhibitors in order to treat cancers, as well as autoimmune and inflammatory diseases.

STAT3 in Disease

Constitutive or hyperexpression of activated STAT3 is present in many malignancies. Oncology experts estimate 70% to 80% of all human cancers have this constitutive expression of activated STAT3.

This hyperexpression of activated STAT3 results in perpetual activation of many genes (see the diagram) that are critical in the pathogenesis of cancer.

To date, there are no STAT3 inhibitors clinically available for patients in the treatment of cancers.

Using our technology platform, we have developed novel STAT3 inhibitors that have shown significant efficacy in vitro and in vivo against several human cancers.

Our lead therapeutic inhibitor, SBT-100 is near completion of its preclinical development and will soon be starting pre-IND studies.


KRAS in Cancer

The oncogene KRAS is mutated in numerous cancers such as pancreatic cancer, lung cancer, colorectal cancer, and many others. Experts estimated that >90% of pancreatic cancers have a mutation in KRAS.

Though the KRAS oncogene was first identified in the 1960's, to date there is still no clinically available drug for patients that can inhibit KRAS.

Our novel anti-KRAS therapeutic inhibitor targets a very common mutant of this oncogene. This anti-mutant KRAS inhibitor is currently in preclinical development.


TNF-alpha and Inflammation

TNF-alpha has been shown to play an important role in the pathogenesis of diseases like rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) (i.e., Crohn's disease and ulcerative colitis).

Current therapies use antibodies that inhibit the effect of TNF-alpha in RA and IBD to bind to targets in the extracellular space on the outside of the cell. 

Our novel proprietary anti-TNF-alpha therapeutic inhibitor is designed to bind TNF-alpha within the cytoplasm of the cell and block it from being released into the extracellular space. We have several anti-TNF-alpha inhibitors that are in preclinical development.

Development Progress

Intracellular proteins are inaccessible to larger biologic molecules, such as traditional monoclonal antibodies and pharmaceutical compounds.

However, we can target and inhibit the functions of these intracellular proteins because our therapeutic agents are ‘small’ enough in size to enter the cells.

After gaining this developmental success, we are now ready to move into the pre-IND phase of development.



Every experiment proves something. If it doesn't prove what you wanted it to prove, it proves something else.

Every experiment proves something. If it doesn't prove what you wanted it to prove, it proves something else.